Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA: AZD5851 in Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Countries
- 3
01
Overview
A Phase 2 trial of AZD5851 in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Dec 2023; status: active, not recruiting.
02
Drugs
AZD5851
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06084884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084884.